Bodybliss and Gemoscan Partner to Manage Food Sensitivity for Millions of Filipinos

Bodybliss and Gemoscan Partner to Manage Food Sensitivity for Millions of
Filipinos

The HEMOCODE(TM) Food Intolerance System Now Even Easier to Access for the
Filipino Community

TORONTO, Dec. 5, 2012 (GLOBE NEWSWIRE) -- Bodybliss, the leading chain of
Health and Wellness Centres serving the Filipino-Canadian community, announced
a strategic partnership with Gemoscan Canada, Inc. (TSXV:GES) (MUN:1GE), to
market the HEMOCODE™ Food Intolerance System. The HEMOCODE^TM Food Intolerance
System is a personalized naturopathic nutritional program that promotes
dietary well-being and uses patented technology and services to provide
consultation and recommendations to simplify the management of food
sensitivities.

The 800,000-strong Filipino community in Canada represents the number one
source of immigrants and contract workers for the country, making Tagalog, the
Filipino language, Canada's fastest growing language. Fifty percent of
Canada's Filipinos make the Greater Toronto Area their home.

Filipino Canadians will be able to identify and ask for HEMOCODE^TM at
Bodybliss as the Bodybliss-HEMOCODE^TM Weight Management and Nutrition
Program.The program, will include a comprehensive eight-week personalized
exercise program, providing the Filipino-Canadian community with greater
access to a wellness solution that is commonly understood to to impact weight
imbalance, chronic pain, headaches, fatigue and more.

The Bodybliss-HEMOCODE^TM Weight Management and Nutrition Program will be
available in all seven Bodybliss Wellness Centres across the Greater Toronto
Area beginning in December 2012.

"I am truly excited to launch the Bodybliss-HEMOCODE Weight Management and
Nutritional Program. Food is a very important part of Filipino culture and
with this program we will be able to guide our customers toward making
suitable food choices that can lead to better well-being by mitigating the
potential onset of chronic symptoms and disease," said Dr. Francis Rementilla,
Chief Executive Officer of Bodybliss.

"Bodybliss and its founder, Dr. Rementilla, have been providing superb care
for Toronto's rapidly growing Filipino community for over a decade.A
strategic alliance with Bodybliss will help bring HEMOCODE^TM, our
state-of-the art wellness program, to the Filipino community in Canada, while
also providing us with a platform to reach millions of more consumers in the
Philippines," said Brian Kalish, Chief Executive Officer of Gemoscan Canada,
Inc.

ABOUT BODYBLISS

For more than 12 years, Bodybliss has been caring for Canadian and
Filipino-Canadian families with exceptional physiotherapy, orthopedic and
wellness services. As part of its commitment to excellent care, time is taken
to research and evaluate the latest technologies that enable the best possible
patient care available. Bodybliss was founded and is led by Dr. Francis
Rementilla, RPT, CPED (C), and is supported by a team of Registered
Physiotherapists, Certified Pedorthists and healthcare clinicians.

ABOUT THE HEMOCODE^TM FOOD INTOLERANCE SYSTEM


The HEMOCODE^TM Food Intolerance System is a personalized naturopathic
nutritional program that promotes dietary well-being.It uses patented
technology and services to provide consultation and recommendations to
simplify the management of food sensitivities. The HEMOCODE^TM Food
Intolerance System is one of a growing number of wellness services and
products offered by pharmacies as complementary medical choices. Complementary
medicine is an adjunct to conventional medical practice, incorporating
alternative modalities and therapies with a focus on lifestyle and wellness. A
statistically significant base of practitioners and those using HEMOCODE^TM
report improved dietary wellness and satisfaction.

ABOUT GEMOSCAN CANADA, INC.

Gemoscan is an industry leader in food intolerance management and maintains a
first-to- market position with Canada wide distribution through select retail
partners. Founded in 2003, using its proprietary patented technology, Gemoscan
develops, owns and markets comprehensive food sensitivity and dietary
management solutions for consumers, including the HEMOCODE™ Food Intolerance
System a personalized naturopathically supervised nutritional program that
promotes well-being. Gemoscan is the first and only provider to commercialize
a food intolerance management solution directly to consumers in partnership
with retailers, and today offers the most comprehensive services available.

Gemoscan Canada, Inc. trades its shares on the Toronto Venture Exchange
(TSX-V) under the symbol GES and is quoted on the Munich, Frankfurt and
Stuttgart Stock Exchanges under the symbol 1GE.

Forward-Looking Information

This news release contains certain "forward-looking information." All
statements, other than statements of historical fact that address activities,
events or developments that Gemoscan believes, expects or anticipates will or
may occur in the future. These forward-looking statements reflect the current
expectations or beliefs of Gemoscan based on information currently available
to Gemoscan. Forward-looking statements are subject to a number of significant
risks and uncertainties and other factors that may cause the actual results of
Gemoscan to differ materially from those discussed in the forward-looking
statements, and even if such actual results are realized or substantially
realized, there can be no assurance that they will have the expected
consequences to, or effects on Gemoscan. Any forward-looking statement speaks
only as of the date on which it is made and, except as may be required by
applicable securities laws, Gemoscan disclaims any intent or obligation to
update any forward- looking statement, whether as a result of new information,
future events or results or otherwise. Although Gemoscan believes that the
assumptions inherent in the forward-looking statements are reasonable,
forward-looking statements are not guarantees of future performance and
accordingly undue reliance should not be put on such statements due to the
inherent uncertainty therein.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.

CONTACT: For further information:
         Bodybliss Corporation:
         Dr. Francis Rementilla
         Chief Executive Officer
         416 224 9900
         francis@bodybliss.ca
        
         Gemoscan Canada:
         Brian Kalish
         Chief Executive Officer
         Telephone: 416 650 1200
         bkalish@hemocode.com
        
         Media:
         Leonard Zehr
         Kilmer Lucas Inc.
         T: (416) 833-9317
         leonard@kilmerlucas.com
 
Press spacebar to pause and continue. Press esc to stop.